Orthotopic Liver Transplant (OLT) Recipients With Hepatitis C Virus (HCV) Under Preemptive Treatment

NCT ID: NCT00167557

Last Updated: 2013-11-19

Basic Information

• Recruitment Status: WITHDRAWN
• Clinical Phase: PHASE4
• Study Classification: INTERVENTIONAL
• Study Start Date: 2005-01-31
• Study Completion Date: 2008-03-31

Brief Summary

After a liver transplant, the hepatitis C virus (which destroyed one's own liver) eventually comes back. In many patients, this will eventually cause the loss of the new liver and can also confuse the doctors taking care of them because it is hard to tell the difference between one's body rejecting the new liver and hepatitis. This can cause serious treatment errors that can lead to more severe hepatitis or to rejection of the liver. Some of the drugs used to prevent rejection of one's new liver can cause the hepatitis to come back in a more severe form. This is especially true for the drugs known as corticosteroids.

Right now, the only effective treatment against hepatitis C is a combination of two drugs called interferon and ribavirin. These drugs act by strengthening one's immune system to fight the virus and by directly reducing the reproduction of the virus. Because the treatment with these drugs is associated with many side effects, there is little experience with treating patients after liver transplantation with them.

In the investigators' transplant program, they have decided to treat all patients with hepatitis C as early as possible after transplantation and to follow them closely for the development of hepatitis and side effects of the treatment. The investigators treat one's hepatitis as early as possible, before any actual damage has occurred in the new liver. This approach has been tried before but it has been hard to tell if it has worked or not. The main reason for failure was that many patients could not complete the treatment due to side effects. The investigators' purpose is to treat those side effects aggressively so that most patients can complete the treatment course.

The purpose of this study is to collect all the data regarding the investigators' treatment protocol so that they will be able to learn if this form of treatment is beneficial.

The study includes performing liver biopsies at scheduled times after one's liver transplant and for scheduled blood tests to see how much virus is still in the blood. If patients show signs that they are not responding to treatment they will be removed from the study.

Detailed Description

HCV recurs in the transplanted liver almost invariably. The clinical course is variable and ranges from no hepatitis to severe aggressive hepatitis with cirrhosis. Factors that affect outcome are high viral load prior to OLT, genotype, and immunosuppressive regimen. Recent studies indicate that the severity of recurrence is increasing with longer follow up, and longevity of both graft and patient is compromised by HCV. Viral load appears to be particularly affected by corticosteroids. The impact of mycophenolate mofetil and tacrolimus is not certain. The results of re-transplantation are generally poor and seem to be a non-cost beneficial way to deal with recurrence HCV cirrhosis. Additionally, re-transplantation deprives other patients from getting OLT in a timely fashion.

Recent studies have shown that with intensive alpha interferon and ribavirin treatment, up to 40% of patients can be cleared of virus as measured by PCR. Thus, despite the cost and side effects of this treatment, it appears justified to treat recurrence preemptively.

Due to the deleterious effects of high dose Corticosteroids it seems logical to attempt to withdraw them as soon as possible from treatment. MMF is often incompatible with interferon and ribavirin treatment due to leukopenia and anemia. The same is true for sirolimus. Thus, most patients will eventually be treated with Tacrolimus monotherapy. Presently, numerous patients end up being treated with Tacrolimus monotherapy as part of the reduction in immune suppression, which occurs over time. There is, however, very little prospective data regarding Tacrolimus monotherapy and almost no data on the specific issue of monotherapy in HCV patients. Even less is known with respect to this type of treatment while using interferon and ribavirin.

Our purpose in this protocol is to examine both the effect of preemptive antiviral treatment on recurrent HCV and the effect of Tacrolimus monotherapy in this setting. This may be important as more and more programs are turning to preemptive anti viral treatment and the issue of appropriate immune suppression becomes seminal to this discussion.

Aims

1. To determine the safety and efficacy of PEG interferon and ribavirin in the treatment of HCV recurrence after OLT.

2. To determine the effectiveness and safety of maintenance dose of PEG interferon to delay progression of fibrosis and histologic damage, in non-responders to the initial regimen of PEG interferon and ribavirin.

3. To determine the effect of early prednisone withdrawal in the rate of response to treatment with PEG interferon and ribavirin.

4. To assess the feasibility of Tacrolimus monotherapy in patients undergoing treatment for HCV recurrence post transplant.

Conditions

Hepatitis C

Keywords

Liver Transplantation

Study Design

• Allocation Method: NON_RANDOMIZED
• Intervention Model: SINGLE_GROUP
• Primary Study Purpose: TREATMENT
• Blinding Strategy: NONE

Study Groups

Single Arm Study

Group Type: EXPERIMENTAL

Pegylated Interferon

Intervention Type: DRUG

180mcg SC weekly starting 30 days post transplant

Ribavirin

Intervention Type: DRUG

goal dose 13mg/kg starting 120 days post transplant for a minimum of 48 wks

Liver Biopsy

Intervention Type: PROCEDURE

Liver biopsies performed at 9 points in time from time of liver transplant

Interventions

Pegylated Interferon

180mcg SC weekly starting 30 days post transplant

Intervention Type: DRUG

Ribavirin

goal dose 13mg/kg starting 120 days post transplant for a minimum of 48 wks

Intervention Type: DRUG

Liver Biopsy

Liver biopsies performed at 9 points in time from time of liver transplant

Intervention Type: PROCEDURE

Eligibility Criteria

Inclusion Criteria

1. Adult male or female patients between 18 and 70 years of age

2. All liver transplant patients with a positive HCV RNA by PCR within 30 days after transplant.

3. No evidence of acute or chronic rejection within 4 weeks of enrollment

4. Compensated liver disease according to the following criteria:

• Hemoglobin > 10 gm/dL;
• Neutrophil count > 1,000/mm3;
• Platelet count > 50,000/mm3;
• Serum creatinine < 2.0 mg/dL.

5. Documentation of adequate contraception in females and males sexually active or of childbearing potential.

Exclusion Criteria

1. Hypersensitivity to alpha interferon and/or ribavirin

2. Previous treatment with interferon and/or ribavirin post liver transplantation

3. HIV

4. Autoimmune hepatitis

5. Active alcohol or substance abuse

6. Non compliance

7. Hemoglobinopathies or hemolytic anemia

8. Clinical significant retinal abnormalities

9. Decompensated cardio-vascular, endocrine, pulmonary, renal, immune, metabolic, dermatologic or psychiatric illness

10. Re-transplantation

• Minimum Eligible Age: 18 Years
• Maximum Eligible Age: 70 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Astellas Pharma US, Inc.

INDUSTRY

Sponsor Role: collaborator

The University of Texas Health Science Center, Houston

OTHER

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

Hadar J Merhav, MD

Role: PRINCIPAL_INVESTIGATOR

The University of Texas Health Science Center, Houston

Locations

Memorial Hermann Hospital

Houston, Texas, United States

Countries

United States

Other Identifiers

Astellas Pharma

Identifier Type: -

Identifier Source: secondary_id

FHIprojectno.JK-04-002

Identifier Type: -

Identifier Source: secondary_id

HSC-MS-04-0346

Identifier Type: -

Identifier Source: org_study_id